Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

作者
Veronica Mariotti,David B. Page,Oksana Davydov,Didier B. Hans,Clifford A. Hudis,Sujata N Patil,Siddharth Kunte,Monica Girotra,Azeez Farooki,Monica Nancy Fornier
出处
期刊:Journal of bone oncology [Elsevier BV]
卷期号:7: 32-37 被引量:36
标识
DOI:10.1016/j.jbo.2016.10.004
摘要

INTRODUCTION: Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care screening tool for fracture risk is bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA). The fracture risk assessment tool (FRAX®) may be used in conjunction with BMD to identify additional osteopenic patients at risk of fracture who may benefit from a bone-modifying agent (BMA). The trabecular bone score (TBS), a novel method of measuring bone microarchitecture by DXA, has been shown to be an independent indicator of increased fracture risk. We report how the addition of TBS and FRAX®, respectively, to BMD contribute to identification of elevated fracture risk (EFR) in postmenopausal breast cancer patients treated with AIs. METHODS: 100 patients with early stage hormone-positive breast cancer treated with AIs, no prior BMAs, and with serial DXAs were identified. BMD and TBS were measured from DXA images before and following initiation of AIs, and FRAX® scores were calculated from review of clinical records. EFR was defined as either: BMD ≤-2.5 or BMD between -2.5 and -1 plus either increased risk by FRAX® or degraded microstructure by TBS. RESULTS: At baseline, BMD alone identified 4% of patients with EFR. The addition of FRAX® increased detection to 13%, whereas the combination of BMD, FRAX® and TBS identified 20% of patients with EFR. Following AIs, changes in TBS were independent of changes in BMD. On follow-up DXA, BMD alone detected an additional 1 patient at EFR (1%), whereas BMD+ FRAX® identified 3 additional patients (3%), and BMD+FRAX®+TBS identified 7 additional patients (7%). CONCLUSIONS: The combination of FRAX®, TBS, and BMD maximized the identification of patients with EFR. TBS is a novel assessment that enhances the detection of patients who may benefit from BMAs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冰棍发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
3秒前
JamesPei的应助被漂亮的火龙果采纳,获得30
3秒前
胡博士发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
3秒前
科研通AI2S的应助被Ethan采纳,获得10
4秒前
4秒前
李丙首完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
Nole的应助被卓卓卓采纳,获得10
5秒前
6秒前
小蘑菇的应助被小明采纳,获得10
6秒前
木玉成约完成签到,获得积分10
6秒前
Fei完成签到 ,获得积分10
7秒前
7秒前
tt666完成签到,获得积分10
7秒前
追风少年完成签到,获得积分10
7秒前
暗潮雷场发布了新的文献求助30
8秒前
8秒前
小布丁完成签到 ,获得积分10
8秒前
8秒前
9秒前
9秒前
9秒前
9秒前
9秒前
9秒前
nnn完成签到,获得积分10
11秒前
杨启军发布了新的文献求助10
11秒前
OoO完成签到,获得积分10
12秒前
JM完成签到 ,获得积分10
12秒前
xixi完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181460
求助须知:如何正确求助?哪些是违规求助? 9571362
关于积分的说明 21817839
捐赠科研通 7777938
什么是DOI,文献DOI怎么找? 3433494
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479550